97.17

1.61% -1.59

Blueprint Medicines Corp (BPMC)

Overview News Price History Option Chain Financials Why BPMC Down? Discussions Forecast

Blueprint Medicines Corp stock is traded at $97.17, with a volume of 621.84K. It is down -1.61% in the last 24 hours and up +18.43% over the past month. Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Previous Close:

$98.76

Open:

$100.04

24h Volume:

621.84K

Relative Volume:

0.59

Market Cap:

$6.76B

Revenue:

$434.41M

Net Income/Loss:

$-128.05M

P/E Ratio:

-46.05

EPS:

-2.11

Net Cash Flow:

$-250.52M

1W Performance:

-7.14%

1M Performance:

+18.43%

6M Performance:

-3.63%

1Y Performance:

-10.31%

1-Day Range:

$97.08

$101.34

1-Week Range:

$97.08

$104.78

52-Week Range:

$73.04

$121.90

Blueprint Medicines Corp Stock (BPMC) Company Profile

Name

Blueprint Medicines Corp

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

617-374-7580

Address

45 SIDNEY STREET, CAMBRIDGE, MA

Employee

649

Twitter

@BlueprintMeds

Next Earnings Date

2024-10-30

Latest SEC Filings

BPMC's Discussions on Twitter

Compare BPMC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BPMC Blueprint Medicines Corp	97.17	6.76B	434.41M	-128.05M	-250.52M	-2.11
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-20-25	Resumed	Morgan Stanley	Equal-Weight
Mar-18-25	Initiated	Wolfe Research	Outperform
Mar-17-25	Initiated	Jefferies	Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Nov-14-24	Initiated	JP Morgan	Overweight
Oct-24-24	Initiated	UBS	Neutral
May-14-24	Initiated	Stephens	Overweight
May-06-24	Upgrade	Leerink Partners	Underperform → Market Perform
Oct-27-23	Upgrade	Oppenheimer	Perform → Outperform
Aug-21-23	Reiterated	Needham	Buy
Jul-31-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jun-05-23	Downgrade	SVB Securities	Market Perform → Underperform
Jan-03-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-14-22	Initiated	Needham	Buy
Nov-02-22	Downgrade	Oppenheimer	Outperform → Perform
Sep-14-22	Initiated	Berenberg	Buy
Jul-08-22	Initiated	Oppenheimer	Outperform
Jun-27-22	Initiated	Wells Fargo	Underweight
Jun-10-22	Downgrade	Citigroup	Neutral → Sell
Jun-01-22	Upgrade	Jefferies	Hold → Buy
Mar-01-22	Initiated	Citigroup	Neutral
Feb-17-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jan-25-22	Upgrade	Stifel	Hold → Buy
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Sep-30-21	Resumed	Stifel	Hold
Jun-04-21	Resumed	Robert W. Baird	Outperform
Mar-31-21	Initiated	Credit Suisse	Neutral
Dec-03-20	Initiated	Stifel	Hold
Nov-02-20	Reiterated	H.C. Wainwright	Buy
Nov-02-20	Downgrade	Jefferies	Buy → Hold
Oct-30-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-15-20	Reiterated	H.C. Wainwright	Buy
May-05-20	Initiated	Barclays	Equal Weight
Mar-17-20	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-28-20	Initiated	BMO Capital Markets	Market Perform
Jan-27-20	Initiated	BMO Capital Markets	Market Perform
Nov-06-19	Upgrade	Raymond James	Outperform → Strong Buy
Oct-22-19	Initiated	JMP Securities	Mkt Outperform
Oct-03-19	Initiated	H.C. Wainwright	Buy
Sep-12-19	Upgrade	Raymond James	Mkt Perform → Outperform
Aug-29-19	Initiated	Piper Jaffray	Neutral
Aug-15-19	Resumed	Raymond James	Mkt Perform
Jul-18-19	Initiated	Deutsche Bank	Buy
May-23-19	Resumed	Goldman	Buy
Apr-03-19	Initiated	Morgan Stanley	Overweight
Sep-25-18	Initiated	Leerink Partners	Outperform
Dec-11-17	Reiterated	Goldman	Buy

View All

Blueprint Medicines Corp Stock (BPMC) Latest News

May 07, 2025

Insider Sell: Christina Rossi Sells Shares of Blueprint Medicines Corp (BPMC) - GuruFocus

May 07, 2025

Blueprint Medicines Executives Sell Shares - TradingView

May 07, 2025

Blueprint Medicines at The Citizens JMP Life Sciences Conference: Strategic Insights - Investing.com

May 07, 2025

Amarin (NASDAQ:AMRN) & Blueprint Medicines (NASDAQ:BPMC) Financial Survey - Defense World

May 07, 2025

May 05, 2025

Blueprint Medicines (NASDAQ:BPMC) Upgraded at StockNews.com - Defense World

May 05, 2025

Blueprint Medicines’ (BPMC) Buy Rating Reiterated at HC Wainwright - Defense World

May 05, 2025

May 03, 2025

Blueprint Medicines First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

May 03, 2025

Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2025 Earnings Call Transcript - Insider Monkey

May 03, 2025

May 02, 2025